Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic H...(ed at least comparable efficacy and comp...),Health

Albuferon 900-mcg Every Two Weeks (Albuferon 900 Q2w)

-- Based on an intention-to-treat (ITT) analysis, 58.5% of patients in the

Albuferon 900 Q2w treatment group achieved SVR, vs. 57.9% for

peginterferon alfa-2a administered every week.

-- In heavier patients (75 kg or heavier) who were treatment-adherent,

74.2% of those in the Albuferon 900 Q2w treatment group achieved SVR,

versus 53.3% for peginterferon alfa-2a.

-- Among all treatment-adherent patients in the Albuferon 900 Q2w

treatment group, 72.3% achieved SVR, versus 66.7% for peginterferon

alfa-2a.

-- Based on the SF-36 Health Survey, patients in the Albuferon 900 Q2w

treatment group reported less impairment of health-related quality of

life, compared with patients in the peginterferon alfa-2a treatment

group, as measured by both physical component and mental component SF-

36 summary measures at all time-points throughout the 48-week treatment

period.

-- Significantly fewer working patients in the Albuferon 900 Q2w treatment

group reported missing 7 days or more of work during the month prior to

their visits at Weeks 12 and 24, vs. the peginterferon alfa-2a group

(p<.05; Week 12: 4.2% for Albuferon 900 Q2w vs. 18.1% for

peginterferon alfa-2a; Week 24: 5.3% for Albuferon 900 Q2w, vs. 20.3%

for peginterferon alfa-2a).

-- The rate of discontinuations due to adverse events was 9.3% in the

Albuferon 900 Q2w treatment group, vs. 6.1% in the peginterferon alfa-

2a group. Adverse events observed were those typically expected with

interferon therapy. '/>"/>